Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cubist Pharmaceuticals and Hydra Biosciences are set to begin the Phase 1 clinical trial of CB-625, a small molecule antagonist of the human Transient Receptor Potential Ankyrin repeat 1 (TRPA1) ion channel.
Subscribe to our email newsletter
Cubist and Hydra have recently identified and completed preclinical testing on a novel small molecule antagonist of the human TRPA1 channel, CB-625 (CB-189,625), and filed for regulatory approval to initiate human clinical studies.
CB-625’s mechanism of action in peripheral pain fibers distinguishes it from all other classes of analgesics.
The Phase 1 trial is intended to assess the potential of TRPA1 investigational product in treating acute pain and inflammatory conditions.
The open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CB-625 in healthy volunteers is likely to begin in the first quarter of 2012.
Hydra Biosciences president and CEO Russell Herndon said the advancement of CB-625 into the clinic would help in the management of peri-operative pain, reducing reliance on opioids, which are believed to have many side effects.